Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.43 |
| ▸ | PRKACA | P17612 | 2/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.43 |
| ▸ | PRKX | P51817 | 2/20 | 0.43 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.43 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21144797 | 1.00 | MAPK1 (0.50) | MAPK1CYP3A4LMNAROCK2ROCK1 | |
| SCHEMBL3901670 | 1.00 | MAPK1 (0.50) | MAPK1CYP3A4LMNAROCK2ROCK1 | |
| SCHEMBL3905562 | 0.85 | FPR2 (0.41) | MAPK1CYP3A4LMNAFPR2MME | |
| SCHEMBL3907802 | 0.85 | FPR2 (0.41) | MAPK1CYP3A4LMNAFPR2MME | |
| SCHEMBL6190633 | 0.84 | CNR1 (0.51) | MAPK1CYP3A4LMNAROCK2ROCK1 | |
| SCHEMBL6539275 | 0.84 | CNR1 (0.51) | MAPK1CYP3A4LMNAROCK2ROCK1 | |
| SCHEMBL3897966 | 0.84 | MAPK1 (0.68) | MAPK1CYP3A4ROCK2ROCK1PRKACA | |
| SCHEMBL2973301 | 0.84 | MAPK1 (0.68) | MAPK1CYP3A4ROCK2ROCK1PRKACA | |
| SCHEMBL3959317 | 0.84 | MAPK1 (0.68) | MAPK1CYP3A4ROCK2ROCK1PRKACA | |
| SCHEMBL14022426 | 0.83 | CTRB1 (0.60) | MAPK1CYP3A4ROCK2ROCK1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | ATAD2, ATAD2B, TAF1L | MAPK1 2974/4885CYP3A4 2947/4885LMNA 3265/4885 |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | ATAD2, ATAD2B, TAF1L | MAPK1 2974/4885CYP3A4 2947/4885LMNA 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.